In accordance, we previously indicated that aprepitant reduces the migratory phenotype of different tumor types including esophageal squamous cell carcinoma [41], cervical cancer, [23], and prostate cancer [22] which was correlated with reduced expression of MMP-2 and MMP-9. This evidence concerns the gene MMP2 and cervical carcinoma.